Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treating the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena- . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.
-
Citations
77 Claims
-
1-31. -31. (canceled)
- 32. A method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, wherein the compound is administered to the patient in a dose ranging between 5 and 15 mg of the active ingredient.
- 43. A method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a first compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and a second compound having (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors.
-
74. A pharmaceutical composition comprising:
-
(a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (b) a COX-2 inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a muscoskeletal disease or disorder.
-
-
75. A pharmaceutical composition comprising:
-
(a) a compound having a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, (b) a compound having a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (c) a COX-2 inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a muscoskeletal disease or disorder.
-
-
76. A method for preparing a compound having a selective Dopamine-4 (D4) and 5-HT2A antagonist, reverse agonist or partial agonist activity comprising the following steps:
-
(a) measuring the selective affinity of a test compound to the D4 receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the D4 receptor in respect to all the other Dopamine receptors, and measuring the selective efficacy of the selected compound to the D4 receptor and selecting a compound which is a selective antagonist, inverse agonist or partial agonist of the D4 receptor;
(b) measuring the selective affinity of a test compound to the 5-HT2A receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the 5-HT2A receptor in respect to all the other 5HT receptors, and measuring the selective efficacy of the selected compound to the 5-HT2A receptor and selecting a compound which is a selective antagonist, inverse agonist or partial agonist of the 5-HT2A receptor;
(c) identifying a compound which is selected in (a) and (b); and
(d) preparing the compound identified in (c). - View Dependent Claims (77)
-
Specification